These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16380696)

  • 1. ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome.
    Kasperlik-Załuska AA; Zgliczyński W; Jeske W; Zdunowski P
    Neuro Endocrinol Lett; 2005 Dec; 26(6):709-12. PubMed ID: 16380696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of magnesium valproate on plasma ACTH concentrations in Nelson's syndrome.
    Kasperlik-Załuska A; Migdalska B; Jeske W; Drac-Kaniewska J; Wiśniewska-Woźniak T
    Acta Med Pol; 1989; 30(1-2):9-15. PubMed ID: 2562233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.
    van Aken MO; Pereira AM; van den Berg G; Romijn JA; Veldhuis JD; Roelfsema F
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):765-72. PubMed ID: 15163342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
    Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
    Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome.
    Mercado-Asis LB; Yanovski JA; Tracer HL; Chik CL; Cutler GB
    J Clin Endocrinol Metab; 1997 Feb; 82(2):514-7. PubMed ID: 9024246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sodium valproate on plasma ACTH and cortisol concentrations in Cushing's disease and Nelson's syndrome.
    Kasperlik-Załuska A; Drac-Kaniewska J; Migdalska B; Jeske W; Wiśniewska-Woźniak T
    Endokrynol Pol; 1988; 39(5):245-52. PubMed ID: 2855625
    [No Abstract]   [Full Text] [Related]  

  • 7. The evaluation of sodium valproate in the treatment of Nelson's syndrome.
    Dornhorst A; Jenkins JS; Lamberts SW; Abraham RR; Wynn V; Beckford U; Gillham B; Jones MT
    J Clin Endocrinol Metab; 1983 May; 56(5):985-91. PubMed ID: 6300181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticotropin-releasing hormone (CRH) stimulation in Nelson's syndrome: response of adrenocorticotropin secretion to pulse injection and continuous infusion of CRH.
    Oldfield EH; Schulte HM; Chrousos GP; Gold PW; Benker G; Peterson RE; Cutler GB; Loriaux DL
    J Clin Endocrinol Metab; 1986 May; 62(5):1020-6. PubMed ID: 3007552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease.
    Reincke M; Allolio B; Kaulen D; Jaursch-Hancke C; Winkelmann W
    Klin Wochenschr; 1988 Aug; 66(15):686-9. PubMed ID: 2845188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion.
    Loli P; Berselli ME; Frascatani F; Muratori F; Tagliaferri M
    J Endocrinol Invest; 1984 Apr; 7(2):93-6. PubMed ID: 6327800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
    Katznelson L
    J Clin Endocrinol Metab; 2013 May; 98(5):1803-7. PubMed ID: 23539733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease.
    Julesz J; Laczi F; Janáky T; László F
    Endokrinologie; 1980 Jul; 76(1):68-72. PubMed ID: 6108208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A correlative study between cortisol and ACTH in Cushing's disease following bilateral adrenalectomy and in Nelson's syndrome.
    Kasperlik-Załuska A; Niegowska E; Migdalska B; Jeske W; Zieliński M
    Endokrynol Pol; 1992; 43(3):314-21. PubMed ID: 1345571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is it possible to predict the development of Nelson's syndrome in Cushing's disease after bilateral adrenalectomy?].
    Horký K; Kanka J; Gregorová I; Tomsová Z; Dvoráková J
    Cas Lek Cesk; 1990 May; 129(21):645-9. PubMed ID: 2164450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma ACTH and cortisol responses to TRF, vasopressin or hypoglycemia in cushing's disease and nelson's syndrome.
    Krieger DT; Luria M
    J Clin Endocrinol Metab; 1977 Feb; 44(2):361-8. PubMed ID: 190254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of valproic acid, naloxone and hydrocortisone in Nelson's syndrome and cushing's disease.
    Elias AN; Gwinup G; Valenta LJ
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):151-4. PubMed ID: 6273025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprolactinemia in Cushing's disease and Nelson's syndrome.
    Yamaji T; Ishibashi M; Teramoto A; Fukushima T
    J Clin Endocrinol Metab; 1984 May; 58(5):790-5. PubMed ID: 6323516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome.
    Mullan KR; Leslie H; McCance DR; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 2006 May; 64(5):519-22. PubMed ID: 16649970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of Nelson's syndrome with sodium valproate.
    Kelly W; Adams JE; Laing I; Longson D; Davies D
    Clin Endocrinol (Oxf); 1988 Feb; 28(2):195-204. PubMed ID: 2844446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective longitudinal study of Pasireotide in Nelson's syndrome.
    Daniel E; Debono M; Caunt S; Girio-Fragkoulakis C; Walters SJ; Akker SA; Grossman AB; Trainer PJ; Newell-Price J
    Pituitary; 2018 Jun; 21(3):247-255. PubMed ID: 29313180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.